Pacira's Exparel For Nerve Block Use Gets Day-Plus US FDA Panel Review

Pacira believes new clinical trial of post-surgical pain medication will satisfy FDA concerns raised in complete response letter for its supplemental NDA.

FDA entrance sign 2016

More from US FDA Performance Tracker

More from Regulatory Trackers